<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="918">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749138</url>
  </required_header>
  <id_info>
    <org_study_id>102453081873</org_study_id>
    <nct_id>NCT00749138</nct_id>
  </id_info>
  <brief_title>Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy</brief_title>
  <official_title>Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bader, Ted, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bader, Ted, M.D.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in
      chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Six different dosages of tamoxifen will be given for 14 days with safety and viral loads
      being measured.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>No significant changes in ALT or total bilirubin</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>HCV RNA reduction</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open label giving of tamoxifen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen</intervention_name>
    <description>giving drug tamoxifen</description>
    <arm_group_label>tamoxifen</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HCV RNA positive.

          2. failed standard therapy

        Exclusion Criteria:

          1. Cirrhosis on biopsy

          2. Severe medical or psychiatric conditions that would make the evaluation difficult

          3. Tamoxifen is a pregnancy category D drug so pregnant women must be excluded.

          4. Patients with coumadin cannot be used from a drug interaction.

          5. Active use of alcohol or illegal substances -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ted Bader</last_name>
    <role>Principal Investigator</role>
    <affiliation>OUHSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <lastchanged_date>March 7, 2010</lastchanged_date>
  <firstreceived_date>September 4, 2008</firstreceived_date>
  <responsible_party>
    <name_title>Ted Bader, MD</name_title>
    <organization>Ted Bader, MD</organization>
  </responsible_party>
  <keyword>hepatitis C, tamoxifen</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
